Hoffa's Fat Pad Impingement (HFPI)

Boston Children's Hospital

Status: Not yet enrolling

Conditions: Hoffa's Fat Pad Impingement

Treatments: Drug: methylprednisolone acetate and lidocaine; Drug: Saline injection (Octreotide LAR placebo)

Study type: Interventional

Funder types: Other

Identifiers

NCT07255248

IRB-P00051842

Details and patient eligibility

About

The aim of the study is to investigate treatment outcomes for refractory anterior knee pain due to Hoffa's Fat Pad Impingement (HFPI) in young female athletes. Specifically, the study team will study pediatric female athletes with HFPI, and treatment outcomes of US-guided Hoffa's Fat Pad (HFP) corticosteroid injection compared to standard care (physical therapy, bracing, no injection) and saline injection. There will be two arms in this study, 1, a corticosteroid injection and physical therapy and 2, physical therapy and a saline injection. The intent of this study is to measure treatment outcomes, and the research team is not looking at the safety and effectiveness of the lidocaine-methylprednisolone mixture.

Enrollment: 62 estimated patients

Sex: Female

Ages: 12 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of HFPI (defined as pain to palpation over the medial or lateral aspect of the infrapatellar fat pad, and/or positive hoffa test which is performed by exerting direct pressure over the infrapatellar fat pad as the knee is passively moved from flexion to extension; pain is positive hoffa test)
• Age 12-18 years
• Patients who identify as female
• Organized sports participation is defined as any adult-led game or sport in which three or more people play and/or practice together regularly in a league or association or an adult-led individual athletic activity. Non-organized sport is excluded such as free play.
• Xray and non-contrast MRI of the knee must have been completed for the symptomatic knee
• Must have completed physician-prescribed course of physical therapy for 6-8 weeks

Exclusion criteria

• History of patellar dislocation or subluxation, Ehlers-Danlos syndrome, patellar tendinitis/tendinosis, quadriceps tendinitis/tendinosis, medial plica syndrome, osteochondritis dessicans (OCD) of the knee, knee osteoarthritis, prior knee surgery
• Other concurrent knee derangement such as meniscus or ligament tears
• Radiographic evidence of bony abnormalities other than lateral patellar tilt, patella alta/baja, trochlear dysplasia
• MR positive for internal knee joint derangement, synovitis/inflammatory changes/effusion, OCD
• Patients receiving other knee injections during the study time period (i.e., viscosupplementation injection, Toradol injection)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

62 participants in 2 patient groups, including a placebo group

Control Group: Saline Injection

Placebo Comparator group

Description:

If you are randomized to the control group, you will receive a saline injection to the hoffa's fat pad at your visit. Saline injections are safe for the intended use of being a placebo injection. After your injection, you will be required to continue with physical therapy. You will be sent patient reported outcomes including quality of life, pain interference, symptoms and function, and level of activity at 4 weeks and 8 weeks following your injection.

Treatment:

Drug: Saline injection (Octreotide LAR placebo)

Intervention Group: Corticosteroid Injection

Active Comparator group

Description:

If you are randomized to the intervention group, you will receive an ultrasound guided corticosteroid injection to the hoffa's fat pad at your visit. Ultrasound guided corticosteroids injections are a common and approved procedure for this condition done at Boston Children's Hospital in the sports medicine clinic. You will be sent patient reported outcomes including quality of life, pain interference, symptoms and function, and level of activity at 4 weeks and 8 weeks following your injection.

Treatment:

Drug: methylprednisolone acetate and lidocaine